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• An effective way to cure disease is to prevent 
the development of it all together. 
• One modality to combat disease is cancer 
vaccines that would “program” an individual’s 
immune system to recognize foreign antigens 
by stimulating cytotoxic T lymphocytes (CTL) 
to attack cancer cells expressing a certain 
tumor antigen [1-5].  
• Current vaccine strategies to combat cancer 
include vaccines consisting of lymphocytes, 
which include: helper T lymphocytes (Th), 
dendritic cells (DC), macrophages, or 
reprogrammed oncolytic viruses [1,2]. 
• We developed a mathematical model of tumor 
dynamics in response to a vaccine injection 
composed of lung cancer epitopes (Survivin, 
Kita-Kyushu lung cancer antigen 1 (KKLC1), 
and epidermal growth factor receptor (EGFR)) 
of different fragment sizes (8-12 amino acids 
(aa) long) with the goal of determining which 
epitopes produce a strong immune response. 
INTRODUCTION 
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• The dynamics of the mathematical model, as 
well as parameter values, are borrowed from 
assertions, prior mathematical models, as well 
as through parameter estimation through 
numerical simulations.  
• Our model is based on a previous model 
published by de Pillis et al. [9], but expanded 
to include simplified T cell development and 
more cell populations to better depict the 
immune response to cancer.  
• No patient data was integrated into this model 
yet as this model is in its infancy; a literature 
review shows no prior model with an 
integrated MonteCarlo simulator. 
• Generated data now is theoretical but has 
applicability to the clinical setting. The 
basis for the model is listed below. 
 













• The dynamics of the mathematical model, as 
well as parameter values, are borrowed from 
assertions, prior mathematical models, as well 
as through parameter estimation through 
numerical simulations. 
• Our model is based on a previous model 
published by de Pillis et al. [9], but expanded to 
include simplified T cell development and 
more cell populations to better depict the 
immune response to cancer.  
• No patient data was integrated into this model 
yet as this model is in its infancy; a literature 
review shows no prior model with an integrated 
MonteCarlo simulator. 
• This model has been modified further to 
introduce the addition of lung cancer 
“vaccines” using Monte-Carlo processes to 
simulate an antigen stimulation response to 
different HLA epitopes [9,13,19].  The model is 
as follows: 
• MHC class I molecules are designed to 
recognize peptide fragments of about eight to 
ten aa along with the maximum being 11.  
• With the involvement of intracellular antigens 
for cancer, the selection of the right HLA gene 
complex depends on the sequence involved to 
activate the system.  
• Our results illustrate that amino acid epitopes 
between 8-11 aa long will produce a robust 
immune response, while anything not in this 
estimated range will produce a non-robust 
immune response. 
• This model, although useful in predicting the 
long-term status of a patient, cannot effectively 
predict which antigen epitopes and HLA 
combinations will produce a strong immune 
response due to the current nature of the model.  
 
1Larkin Hospital , Department of Medicine, FL, 2Rowan University SOM, Department of Internal Medicine, NJ,  
3California Health Sciences University, CA 
 
 
Vaccines on the Immune Response 
 
• Equation #1 describes the change in population of a cancerous pathology in 
which the state variable is C. Cancer populations propagate (rc) at a fixed rate 
and die off due to cell-to-cell interactions between NK cells (k1), CTL’s (k2), and 
macrophages (k3). 
• Equation #2 describes the change of NK cell populations in which the state 
variable of this equation is (N). NK cells are born at a fixed rate (Bn) and die off 
(Dn) in proportion to population levels. In addition, NK cells are recruited in 
response to cancer antigen presentation at a fixed rate (Rn and Mn)  as well as 
die off due to cell-cell interactions with cancer (Ln). 
• Equation #3 describes the change of naive CD8 populations in which the state 
variable of this equation is (Tn). Naive CD8 populations are born at a fixed rate 
(Bt) and die off (Dt) in proportion to population levels. Such cells then transition 
from the naive to primed states due to cancer antigen acquisition (Ma) by antigen 
presenting cells at a fixed rate (Mt), which then present the processed cancer 
antigen to naive populations. 
• Equation #4 describes the change of primed CD8 populations in which the state 
variable of this equation is (Te). Naive CD8 populations are primed with cancer 
antigen transition from their naive to primed states to combat cancer (first term) 
and die off (De) in proportion to population levels. Primed CTL populations are 
then influenced due to memory cell recruitment by interlukin-2 (Rr) and are 
inhibited (Ih) by T regulatory cells. 
• Equation #5 describes the change of naive CD4 populations in which the state 
variable of this equation is (Rn). Naive CD4 regulatory populations are born at a 
fixed rate (Br) and die off (Dr) in proportion to population levels. Such cells then 
transition from the naive to primed states due to cancer antigen acquisition (Ma) 
by antigen presenting cells at a fixed rate (Mt), which then present the processed 
cancer antigen to naive populations. 
• Equation #6 describes the change of primed CD4 populations in which the state 
variable of this equation is (Re). Naive CD8 populations are primed with cancer 
antigen transition from their naive to primed states to combat cancer (first term) 
and die off (Dr) in proportion to population levels. Primed CTL populations are 
then influenced due to memory cell recruitment by interlukin-2 (Rr) and are 
inhibited (Ih) by T regulatory cells. 
• Equation #7 describes the change of interleukin-2 concentration in which the 
state variable of this equation is (I2). IL-2 is produced at a constant rate (Ci) by 
primed immune cells, mainly of HTL lineage, and is consumed in varying 
proportions (Rh ,Rt, and Rr) to recruit circulating memory cells to combat cancer 
populations. In addition, IL-2 denatures (Di) in proportion to population levels.  
• Equation #8 describes the change of antigen presenting cells in which the state 
variable of this equation is (Ap). APC populations are primed (Ra) in direct 
proportion to cancer antigen and die off (dA) in proportion to population levels. 
•  Equation #9 describes the change of naive CD4 regulatory populations in 
which the state variable of this equation is (Rn). Naive CD4 regulatory 
populations are born at a fixed rate (Br) and die off (Dr) in proportion to 
population levels. Such cells then transition from the naive to primed states due 
to cancer antigen acquisition (Ma) by antigen presenting cells at a fixed rate 
(Mt), which then present the processed cancer antigen to naive populations. 
• Equation #10 describes the change of primed CD4 regulatory populations in 
which the state variable of this equation is (Re). Naive CD4 regulatory 
populations are primed with cancer antigen transition from their naive to primed 
states to combat cancer (first term) and die off (Dr) in proportion to population 
levels. Primed CTL populations are then influenced due to memory cell 
recruitment by interlukin-2 (Rr). 
• Equation #11 describes the change of macrophage populations in which the 
state variable of this equation is (M). NK cells are primed at a rate (Ra) in 
proportion to cancer antigen  and die off (Dn) in proportion to population levels 
as well as interactions with cancer cells (Ln) .  
• Equations #12 and #13 act as placeholder equations for two variables (Rc and 
Ma) that act as the Monte-Carlo Simulator via a pseudo-number generator that 
affects the output of the other eleven equations 
CONCLUSION 
• In our model, three antigens Survivin, KKLC1, 
and EGFR [24] were utilized from the 
TANTIGEN database to predict an immune 
response once cancer was detected within an 
individual following utilization of a synthetic 
vaccine. 
• We applied mathematical modeling as a tool to 
depict the strength of a host’s immune 
response after it has been subjected to a lung 
tumor vaccine.  
• Here, we showed and can infer that if a 
synthetic epitope is not between 8-11 aa long, 
a host will produce an immune response, but 
that is not ideal to the elimination of cancer 
[26,27].  
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